Author

Biljana Čuljković

Northwestern UniversityORCID 0000-0003-4350-3014Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

Katherine L. B. BordeniD· 2 shared Aksharh Thambipillai· 1 shared Alyssa D. RetiziD· 1 shared Caleb M. EmbreeiD· 1 shared Christian BachiD· 1 shared Daniel Geoffrey TeneniD· 1 shared Emma Lassman· 1 shared Fang ZhouiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Katherine L. B. BordenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 2, 2026

✦ In-depth digest

eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemia

Biljana Čuljković, Leandro Marcelo Martinez, Naiyu Shi…·Katherine L. B. Borden

In acute myeloid leukemia, Ezrin binds eIF4E and anchors active ribosomes in pseudopods for local translation of CD44 and hyaluronan pathway proteins; eIF4E loss impairs mouse engraftment.

1 citation

humanmouse

𝕏 PostBluesky

Molecular BiologybioRxivPreprintFeb 10, 2025

Posttranscriptional activity of the eukaryotic translation initiation factoreIF4E contributes to HoxA9-driven leukemogenesis

Fang Zhou, Biljana Čuljković, Christian Bach…·Daniel Geoffrey Tenen

This study shows that disrupting the interaction between HoxA9 and eIF4E delays AML onset and reduces disease penetrance, suggesting eIF4E as a therapeutic target in HoxA9-driven leukemia.

DOI 10.1101/2025.02.10.637540

mouseexperimental assay

𝕏 PostBluesky